Table of Contents
Telis Bioscience
Telis Bioscience is an American biotechnology company based in Cambridge, Massachusetts.
History
Telis was founded in 2019 by Grigory Khimulya and Kyle Fish.1) 2)
In December 2021, Telis pivoted to focus on developing a COVID-19 vaccine under a new name, Alvea, which launched in January 2022.3)
Organization
Funding
Telis received $2 million from Alameda Research.4)
Personnel
| Name | Position | Notes |
|---|---|---|
| Grigory Khimulya | Co-founder & Chief Executive Officer | - |
| Kyle Fish | Co-founder & Chief Technology Officer | - |
External links
1)
Telis Bioscience - Crunchbase Company Profile & Funding. Crunchbase. Retrieved March 27, 2023, from https://www.crunchbase.com/organization/telis-bioscience
2)
Grigory Khimulya [@grigonomics]. (2020, September 23). “Life update: for the past year @fish_kyle3 and I have been building Telis Bioscience, a venture-backed biotech company in Cambridge, MA engineering high-impact protein therapeutics . We’re hiring! (1/5)” [Tweet]. Twitter. http://archive.today/2023.03.27-011210/https://twitter.com/grigonomics/status/1308768978756567042
3)
McGrath, K. (2022, February 16). Alvea Launches Scalable, Shelf- Stable DNA Vaccine Development against New SARS-CoV-2 Variants. PR Newswire. https://web.archive.org/web/20220513024500/https://www.prnewswire.com/news-releases/alvea-launches-scalable-shelf--stable-dna-vaccine-development-against-new-sars-cov-2-variants-301483557.html
4)
Ashworth, L. (2022, December 19). How to spend a million dollars, by Sam Bankman-Fried. Financial Times. http://archive.today/2023.01.11-055404/https://www.ft.com/content/9a3b4b78-b18b-4d1f-b28b-05a73525aa61